On January 18, 2024, Tarsus Pharmaceuticals, Inc. announced that Jose Trevejo, M.D., Ph.D. would be leaving his role as the Company?s Chief Medical Officer (the ?Transition?), effective as of January 18, 2024 (the ?Transition Date?), and leaving his employment with the Company on February 17, 2024. The functional clinical development and medical affairs department previously led by Dr. Trevejo has been reorganized under the leadership of the Company?s Chief Operating Officer, Sesha Neervannan, Ph.D. The Transition was approved on January 11, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.03 USD | -4.92% | -5.66% | +63.11% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.11% | 1.31B | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- TARS Stock
- News Tarsus Pharmaceuticals, Inc.
- Tarsus Pharmaceuticals, Inc. Announces Executive Changes